唐海林
专长
长期致力于乳腺癌远处器官转移的基础研究。2020-2025连续 6 年入选全球前2%顶尖科学家“年度科学影响力排行榜”的学者；培养博士生、硕士生、博士后以及访问学者等30余人。主持国家自然科学基金6项，省市联合基金（粤佛）重点项目1项，广州市重点研发计划1项， “香江学者”计划1项，其他省部级项目10余项；在Molecular Cancer, Drug Resistance Updates, Research, Nature Communications, Advanced Science, Cancer Letters等期刊上发表通讯作者SCI论文90余篇；
担任Oncology Research杂志主编；Cancer Drug Resistance, Pathology and Oncology Research, Journal of Cancer Metastasis and Treatment等杂志副主编；Research, Cancer Letters, Journal of Translational Internal Medicine, Journal of Integrative Medicine, Frontiers in Bioscience-Landmark等杂志编委；
【联系方式】
tanghl@sysucc.org.cn
广州市东风东路651号2号楼901室
【教育和博士后背景】
1. 1997-2002年 南华大学衡阳医学院，临床医学，本科/学士
2. 2004-2007年 南华大学衡阳医学院，研究生/硕士
3. 2009-2011年 中南大学，研究生/博士
4. 2012-2014年 中山大学，基础医学/博士后
5. 2015-2017年 香港大学，临床医学/博士后/香江学者
【代表性科研项目：主持】
1. 国家自然科学基金面上项目（82473036, 49万）.IRF5调控色氨酸代谢促进三阴乳腺癌远处转移的机制研究. 2025.01-2028.12
2. 国家自然科学基金面上项目（82273399, 52万）. KLF5调控脂肪酸代谢促进乳腺癌远处转移的机制研究. 2023.01-2026.12
3. 国家自然科学基金面上项目（82073117, 57万）. circSLCO1B3在三阴乳腺癌脑转移中的作用及其机制. 2021.01-2024.12
4. 国家自然科学基金面上项目（81772961, 56万）. 环状RNA- crEPSTI1促进三阴乳腺癌生长与转移的机制研究. 2018.01-2021.12
5. 国家自然科学基金面上项目（81472469, 78万）. TV-miR-200b/c靶向抑制HER2/HER3克服乳腺癌对赫赛汀耐药. 2015.01-2018.12
6. 国家自然科学基金青年项目（31100935, 20万）, DADS上调miR-200b和miR-22表达抑制胃癌生长的分子机制研究, 2012.01-2014.12.
7. 省市联合基金（粤佛）重点项目（2022B1515120087, 100万）KLF5调控脂质重编程促进NK/T细胞淋巴瘤进展的机制研究, 2022.10-2025.09.
8. 广州市重点研发计划（202103000020, 100万）鸡血藤有效成分异甘草素抑制三阴乳腺癌脑转移的分子机制研究, 2021.04-2024.03.
9. 广东省科技项目（2016A020214009, 30万）TV-miR-200b/c调控乳腺癌干细胞的分子机制研究. 2016.01-2018.12
10. 广州市科技项目（201607010173, 20万） TET/miR-26a/EZH2环路调控的表观遗传修饰在三阴性乳腺癌中的作用. 2016.01-2018.12
【近5年代表性SCI论文：最后通讯作者】
1. Liu P, Wang Z, Ou X, Wu P, Zhang Y, Wu S, Xiao X, Li Y, Ye F, Tang H. The FUS/circEZH2/KLF5/ feedback loop contributes to CXCR4-induced liver metastasis of breast cancer by enhancing epithelial-mesenchymal transition. Mol Cancer. 2022 Oct 12;21(1):198. (IF:33.9)（高被引论文）
2. Wang Z, Yang L, Wu P, Li X, Tang Y, Ou X, Zhang Y, Xiao X, Wang J, Tang H. The circROBO1/KLF5/FUS feedback loop regulates the liver metastasis of breast cancer by inhibiting the selective autophagy of afadin. Mol Cancer. 2022 Jan 24; 21(1):29. (IF:33.9)
3. Chen Y, Liang J, Chen S, Lin N, Xu S, Miao J, Zhang J, Chen C, Yuan X, Xie Z, Zhu E, Cai M, Wei X, Hou S, Tang H. Discovery of vitexin as a novel VDR agonist that mitigates the transition from chronic intestinal inflammation to colorectal cancer. Mol Cancer. 2024 Sep 13;23(1):196. (IF:33.9)
4. Ou X, Tan Y, Xie J, Yuan J, Deng X, Shao R, Song C, Cao X, Xie X, He R, Li Y, Tang H. Methylation of GPRC5A promotes liver metastasis and docetaxel resistance through activating mTOR signaling pathway in triple negative breast cancer. Drug Resist Updat. 2024 Feb 1;73:101063. (IF:21.7)（高被引论文）
5. Zou Y, Ye F, Kong Y, Hu X, Deng X, Xie J, Song C, Ou X, Wu S, Wu L, Xie Y, Tian W, Tang Y, Wong CW, Chen ZS, Xie X, Tang H. The single-cell landscape of intratumoral heterogeneity and the immunosuppressive microenvironment in liver and brain metastases of breast cancer. Adv Sci (Weinh). 2023 Feb;10(5):e2203699. (IF:14.1)（高被引论文）
6. Liang J, Dai W, Liu C, Wen Y, Chen C, Xu Y, Huang S, Hou S, Li C, Chen Y, Wang W, Tang H. Gingerenone A Attenuates Ulcerative Colitis via Targeting IL-17RA to Inhibit Inflammation and Restore Intestinal Barrier Function. Adv Sci (Weinh). 2024 Jul;11(28):e2400206. (IF:14.1)（高被引论文）
7. Xu R, Du A, Deng X, Du W, Zhang K, Li J, Lu Y, Wei X, Yang Q, Tang H. tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB. J Exp Clin Cancer Res. 2024 Aug 17;43(1):230.(IF: 12.8)（高被引论文）
8. Tang Y, Tian W, Zheng S, Zou Y, Xie J, Zhang J, Li X, Sun Y, Lan J, Li N, Xie X, Tang H. Dissection of FOXO1-Induced LYPLAL1-DT Impeding Triple-Negative Breast Cancer Progression via Mediating hnRNPK/β-Catenin Complex. Research (Wash D C). 2023 Dec 15;6:0289. (IF: 10.9)（高被引论文）
9. Zhang C, Wang S, Lu X, Zhong W, Tang Y, Huang W, Wu F, Wang X, Wei W, Tang H. POP1 Facilitates Proliferation in Triple-Negative Breast Cancer via m6A-Dependent Degradation of CDKN1A mRNA. Research (Wash D C). 2024 Sep 12;7:0472. (IF:10.9)（高被引论文）
10. Zhang J, Huang Z, Song C, Wu S, Xie J, Zou Y, Xie X, Wu T, Yang H, Tang H. PRMT1-Mediated PARP1 Methylation Drives Lung Metastasis and Chemoresistance via P65 Activation in Triple-Negative Breast Cancer. Research (Wash D C). 2025 Sep 8;8:0854. (IF:10.9)
11. Ganesan K, Xu C, Wu S, Sui Y, Du B, Zhang J, Gao F, Chen J, Tang H. Ononin Inhibits Tumor Bone Metastasis and Osteoclastogenesis By Targeting Mitogen-Activated Protein Kinase Pathway in Breast Cancer. Research (Wash D C). 2024 Dec 16;7:0553. (IF:10.9)
12. Li Y, Wu Y, Liang J, Chen P, Xu S, Wang Y, Jiang Z, Zhu X, Lin C, Yu Y, Tang H. Ligustilide Suppresses Macrophage-Mediated Intestinal Inflammation and Restores Gut Barrier via EGR1-ADAM17-TNF-α Pathway in Colitis Mice. Research (Wash D C). 2025 Sep 2;8:0864. (IF:10.9)
13. Shao R, Liu S, Liu W, Song C, Liu L, Zhu L, Peng F, Lu Y, Tang H. Interleukin-33 increases the sensitivity of multiple myeloma cells to the proteasome inhibitor bortezomib through reactive oxygen species-mediated inhibition of nuclear factor kappa-B signal and stemness properties. MedComm (2020). 2024 May 9;5(5):e562. (IF: 10.7)
14. Liu A, Jiang B, Song C, Zhong Q, Mo Y, Yang R, Chen C, Peng C, Peng F, Tang H. Isoliquiritigenin inhibits circ0030018 to suppress glioma tumorigenesis via the miR-1236/HER2 signaling pathway. MedComm (2020). 2023 May 26;4(3):e282. (IF: 10.7)
15. Tan C, Xie G, Wu S, Song C, Zhang J, Yi X, Wang J, Tang H. Simultaneous detection of breast cancer biomarkers circROBO1 and BRCA1 based on a CRISPR-Cas13a/Cas12a system. Biosens Bioelectron. 2024 Aug 15;258:116373. (IF: 10.5)
16. Wu S, Lu J, Zhu H, Wu F, Mo Y, Xie L, Song C, Liu L, Xie X, Li Y, Lin H, Tang H. A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer. Cancer Lett. 2024 Jan 28:581:216508. (IF: 10.1)（高被引论文）
更新时间：2025.12.5
